US58933Y1055 - Common Stock - After market: 102.93 -0.01 (-0.01%)
NYSE:MRK (2/3/2023, 7:04:00 PM)-0.52 (-0.5%)
|GICS Sector||Health Care|
|Earnings (Last)||02-02 2023-02-02/amc||Earnings (Next)||04-27 2023-04-27/amc|
|Ins Owners||0.06%||Inst Owners||74.25%|
Find more stocks on New York Stock Exchange, Inc.
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 68,000 full-time employees. The firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. The firm's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The firm sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.
MERCK & CO. INC.
2000 Galloping Hill Road
Kenilworth NEW JERSEY 07033
CEO: Kenneth C. Frazier
The major indexes continued to run despite mixed-to-weak earnings.
Merck's (MRK) blockbuster drug Keytruda, with chemotherapy, met the main goal of progression free survival ((PFS)) in patients with a type of cancer of the uterus in a phase 3...
An earnings-inspired rally in Meta Platforms (META) fueled gains in the Nasdaq and S&P 500 on Thursday, adding to Fed-related gains registered the day before
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy.
MRK earnings call for the period ending December 31, 2022.
Here you can normally see the latest stock twits on MRK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.